title: Routine prenatal screening for HIV in a low-prevalence setting.
abstract: BACKGROUND
  The objectives of this study were to assess the effect of British Columbia's June 1994 guidelines for prenatal HIV screening on the rate of maternal-fetal HIV transmission and to estimate the cost-effectiveness of such screening.
  
  
  METHODS
  The authors conducted a retrospective review of pregnancy and delivery statistics, HIV screening practices, laboratory testing volume, prenatal and labour management decisions of HIV-positive women, maternal-fetal transmission rates and associated costs.
  
  
  RESULTS
  Over 1995 and 1996, 135,681 women were pregnant and 92,645 carried to term. The rate of HIV testing increased from 55% to 76% of pregnancies on chart review at one hospital between November 1995 and November 1996. On the basis of seroprevalence studies, an estimated 50.2 pregnancies and 34.3 (95% confidence interval 17.6 to 51.0) live births to HIV-positive women were expected. Of 42 identified mother-infant pairs with an estimated date of delivery during 1995 or 1996, 25 were known only through screening. Of these 25 cases, there were 10 terminations, 1 spontaneous abortion and 14 cases in which the woman elected to carry the pregnancy to term with antiretroviral therapy. There was one stillbirth. One instance of maternal-fetal HIV transmission occurred among the 13 live births. The net savings attributable to prevented infections among babies carried to term were $165,586, with a saving per prevented case of $75,266.
  
  
  CONCLUSIONS
  A routine offer of pregnancy screening for HIV in a low-prevalence setting reduces the rate of maternal-fetal HIV transmission and may rival other widely accepted health care expenditures in terms of cost-effectiveness.
authors.affiliation: British Columbia Centre for Disease Control Society, Vancouver. david.patrick@bccdc.hnet.bc.ca
authors.forename: D M
authors.initials: DM
authors.lastname: Patrick
authors.forename: D M
authors.initials: DM
authors.lastname: Money
authors.forename: J
authors.initials: J
authors.lastname: Forbes
authors.forename: S R
authors.initials: SR
authors.lastname: Dobson
authors.forename: M L
authors.initials: ML
authors.lastname: Rekart
authors.forename: D A
authors.initials: DA
authors.lastname: Cook
authors.forename: P J
authors.initials: PJ
authors.lastname: Middleton
authors.forename: D R
authors.initials: DR
authors.lastname: Burdge
mesh_terms: D001955:British Columbia / Q000453:epidemiology; D002170:Canada; D003362:Cost-Benefit Analysis; D005260:Female; D015658:HIV Infections / Q000175:diagnosis* / Q000453:epidemiology / Q000208:ethnology / Q000517:prevention & control* / Q000635:transmission; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D008403:Mass Screening / Q000191:economics / Q000706:statistics & numerical data; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000175:diagnosis* / Q000453:epidemiology / Q000208:ethnology / Q000821:virology; D011295:Prenatal Care / Q000191:economics / Q000706:statistics & numerical data; D015995:Prevalence; D012189:Retrospective Studies; D012307:Risk Factors